CIM
LXRX icon

CIM Investment Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

CIM Investment Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-18,635
Closed -$37K – 273
2020
Q2 		$37K Buy
18,635
+3,176
+21% +$6.22K 0.01% 252
2020
Q1 		$30K Hold
15,459
– – 0.01% 194
2019
Q4 		$64K Sell
15,459
-12,079
-44% -$46.5K 0.03% 234
2019
Q3 		$83K Hold
27,538
– – 0.03% 311
2019
Q2 		$173K Sell
27,538
-562
-2% -$3.36K 0.06% 305
2019
Q1 		$156K Buy
+28,100
New +$171K 0.06% 304
2018
Q4 		– Sell
-19,684
Closed -$210K – 318
2018
Q3 		$210K Hold
19,684
– – 0.08% 308
2018
Q2 		$236K Sell
19,684
-23,025
-54% -$236K 0.08% 312
2018
Q1 		$366K Buy
42,709
+26,973
+171% +$249K 0.12% 228
2017
Q4 		$155K Sell
15,736
-190
-1% -$1.97K 0.05% 318
2017
Q3 		$196K Hold
15,926
– – 0.07% 307
2017
Q2 		$262K Buy
+15,926
New +$247K 0.09% 302
2016
Q2 		– Sell
-22,753
Closed -$272K – 299
2016
Q1 		$272K Buy
+22,753
New +$239K 0.12% 212

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CIM Investment Management's LXRX Position: Q3 2020 in Review

CIM Investment Management sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2020, closing a stake of 18,635 shares — an estimated $37K sold.

CIM Investment Management first reported a position in LXRX in Q1 2016 and held it in 13 quarters. The position peaked at $366K in Q1 2018. 91 funds tracked by Wall St. Rank hold LXRX as of Q3 2020.

  • CIM Investment Management reported no remaining Lexicon Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • CIM Investment Management sold 18,635 Lexicon Pharmaceuticals shares in Q3 2020, an estimated $37K.
  • CIM Investment Management first reported a position in Lexicon Pharmaceuticals in Q1 2016 and held it in 13 quarters.
  • CIM Investment Management's Lexicon Pharmaceuticals position peaked at $366K in Q1 2018.
  • 91 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2020.

Based on CIM Investment Management's 13F filing for Q3 2020, filed 16 Nov 2020.